Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05619861 | Apr 2020 → Jan 2023 | B-cell non-Hodgkin lymphoma, T-cell leukemia, plasma cell myeloma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-28 | Hebei Senlang Biotechnology Inc., Ltd. | Results 重磅预告｜森朗生物6项前沿成果即将亮相ASH2025 senlangbio.com ↗
其中，靶向CD7的CAR-T 细胞疗法 SENL101在治疗复发/难治性T-ALL/LBL患者的I期临床试验（CARMA-I研究）结果表现亮眼，展现出卓越的疗效和较同类产品更有临床优势的安全性。 |
| 2023-09-05 | Hebei Senlang Biotechnology Inc., Ltd. | Regulatory 森朗生物靶向CD7的CAR-T细胞产品（SENL101自体T细胞注射液）获美国FDA授予“孤儿药”认定 senlangbio.com ↗ |
| 2022-08-04 | Hebei Senlang Biotechnology Inc., Ltd. | Results Blood期刊特邀专家对森朗生物研发的无需基因编辑的自然选择CD7 CAR-T研究成果进行点评 senlangbio.com ↗
第28天时，19 名患者骨髓微小残留病阴性完全缓解 (CR)；9名有髓外病灶的患者中，5名实现髓外CR。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-15 | Hebei Senlang Biotechnology Inc., Ltd. | 森朗生物携手 Tempest Therapeutics 推进体内 CAR-T 新药 TPST-4003 中国临床开发 senlangbio.com ↗ |
| 2025-11-28 | Hebei Senlang Biotechnology Inc., Ltd. | 重磅预告｜森朗生物6项前沿成果即将亮相ASH2025 senlangbio.com ↗ |
| 2023-09-05 | Hebei Senlang Biotechnology Inc., Ltd. | 森朗生物靶向CD7的CAR-T细胞产品（SENL101自体T细胞注射液）获美国FDA授予“孤儿药”认定 senlangbio.com ↗ |
| 2022-08-04 | Hebei Senlang Biotechnology Inc., Ltd. | Blood期刊特邀专家对森朗生物研发的无需基因编辑的自然选择CD7 CAR-T研究成果进行点评 senlangbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05619861 ↗ |
| Modality | Cell therapy | “Autologous CAR-T cells” NCT05619861 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05619861 ↗ |